Last updated: 2026-10-13 07:28:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Corvus Pharmaceuticals, Inc. (CRVS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $10.03, with a market capitalisation of $884.95M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.39 to $26.95. This page covers its latest market performance, valuation, price trends and company information.
$884.95M | |
$10.43 | |
$26.95 | |
$0.61 | |
$10.52 | |
584.45K | |
964.32K | |
-- | |
$26.95 | |
$6.39 | |
-- | |
-- |
Corvus Pharmaceuticals, Inc. (CRVS) last closed at $10.52 as of 2026-10-12 23:31:00, unchanged from the previous close of $10.52.
During the latest regular trading session, CRVS traded between $0.61 and $26.95, with a volume of 584.45K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Corvus Pharmaceuticals, Inc. (CRVS) moved from $10.90 to $10.03, representing a decline of 7.97% ($0.87).
The stock traded between $9.82 and $11.15 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.20 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 17.7%
CRVS is currently trading at $10.03, placing it 17.7% of the way from its 52-week low of $6.39 to its 52-week high of $26.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 37 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Corvus Pharmaceuticals, Inc. (CRVS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.